Observational studyBMC pregnancy and childbirth2026
Relationship between continuous maternal intrapartum and postpartum glucose monitoring metrics and neonatal outcomes and postpartum glucose metabolism in individuals with gestational diabetes.
Observational study in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05067075 (Role of Continuous Glucose Monitoring Systems), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Continuous Glucose Monitoring Systems (CGMS) for Intrapartum Metabolic Control in Gestational Diabetic (GDM)Women
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundContinuous glucose monitoring (CGM) improves maternal and neonatal outcomes in pregnancies complicated by preconception diabetes. CGM measurements may help optimize intrapartum and postpartum glycemic management in pregnant women with GDM. We investigated the use of blinded CGM-derived metrics during labor, delivery, and postpartum supplementary to normally monitored glucose measures in women with GDM to study neonatal outcomes and postpartum glucose metabolism.
methodsThis prospective observational study evaluated 60 pregnant women with gestational diabetes mellitus (GDM) during the peripartum and postpartum periods. Of these, 35% were managed with diet alone, while 65% required pharmacologic therapy (insulin, metformin, or both). Participants wore a blinded continuous glucose monitor (Dexcom G6 Pro) for 10 days, beginning 1–3 days before delivery. At 6–18 weeks postpartum, all underwent a 75-g oral glucose tolerance test (OGTT), with a subset (n = 28) also using blinded CGM. Univariate and logistic regression analyses assessed associations between CGM metrics in the 24 h preceding delivery and neonatal hypoglycemia or NICU admission.
resultsInfants of women having an induced vaginal or unplanned caesarean delivery (C-section) were significantly more likely than infants delivered by repeat C-section to have neonatal hypoglycemia (p = 0.005). No significant correlations between maternal CGM-derived metrics and postnatal adaptation in the newborn were found and none of the models trained to predict neonatal hypoglycemia or intensive unit (NICU) admission showed satisfactory power. While only modest associations between postdelivery CGM metrics and postpartum OGTT values were observed, there were strong correlations between postpartum CGM metrics and OGTT-derived values.
conclusionIn GDM, intrapartum CGM-based metrics were not associated with adverse neonatal outcomes. Future investigations with a larger cohort are needed to assess intra-and postpartum CGM-metrics in women with GDM and their association with neonatal outcomes and OGTT results.
trial registrationClinicalTrials.gov, NCT05067075 (initiation 11/1/2021).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.